Swedish medical technology firm Elekta reported a net loss of 381 million Swedish Kronor for its fourth quarter, impacted by a 1.064 billion Swedish Kronor non-cash impairment from discontinued research and development projects, the company said.
For the full year, net income fell to 240 million Swedish Kronor.
Despite this, net sales in constant exchange rates rose 6% in the fourth quarter to 5.156 billion Swedish Kronor, driven by Europe and APAC.
The company achieved its best Q4 gross margin in five years at 40.3% and generated strong cash flow of 1.248 billion Swedish Kronor.
Elekta expects year-over-year net sales growth and expanding margins, according to the company.
More from this issuer
Related coverage
Elekta's new chief executive is replacing three top executives, including the finance chief, in a broad management overhaul aimed at improving the Swedish medical-device maker's performance.
Elekta AB has introduced a new long-term incentive plan that ties executive bonuses to the sales of its advanced radiation-therapy technology, a move approved at its annual general meeting on Thursday.
Elekta AB reported a drop in first-quarter sales and profit margins, setting a challenging backdrop for incoming Chief Executive Jakob Just-Bomholt.
Elekta AB said it received U.S. regulatory clearance for its Leksell Gamma Knife radiosurgery system to treat a form of drug-resistant epilepsy in adults.